Pinter A, et al. - Researchers conducted this case series and literature review to explore whether brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, improves psoriatic lesions and relieves associated symptoms in patients with moderate-to-severe psoriasis. In early dose-finding studies with brodalumab in moderate to severe plaque psoriasis for an induction phase of 12 weeks, optimal responses occurred every 2 weeks at a dose of 210 mg by subcutaneous injection at 0, 1, and 2 weeks. At this recommended dosage, all patients in the current series of cases received brodalumab. In patients with moderate to severe psoriasis, including those with psoriatic arthritis, brodalumab quickly improves psoriatic lesions and relieves related symptoms. These advantages are also obvious in patients who have failed to respond to other biologics and are also retained on a long-term basis. During the normal induction phase of 12 weeks and with prolonged treatment (52 to 120 weeks), the drug is well tolerated as in the current series of cases.